Everolimus: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Everolimus. Educational only — not medical advice.
Labeled uses
1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer TORPENZ tablets are indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Source: FDA labeling via NIH DailyMed (set 4c0075dd…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.